COMMUNIQUÉS West-GlobeNewswire

LifeMD Reports Second Quarter 2026 Results
05/08/2026
Second quarter 2026 revenue of $47.3 million, within the Company’s guidance range of $47 million to $50 million; adjusted EBITDA loss of approximately $3.5 million, improving approximately 21% sequentially. [...]
PacBio Appoints Mark Van Oene as President and Chief Executive Officer
05/08/2026
Christian Henry to Transition from President and Chief Executive Officer Following Six Years of Leadership; Effective August 5, 2026 MENLO PARK, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Pacific Biosciences of [...]
Emergent BioSolutions Commits to Cross-Sector Collaboration Against Biological Threats in an Evolving Global Security Environment
05/08/2026
GAITHERSBURG, Md., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE:EBS), a global biodefense company, today highlighted the increasing importance of biological threat preparedness as allied nations [...]
Emergent BioSolutions Reports Second Quarter 2026 Financial Results
05/08/2026
Second Quarter 2026 Total Revenues of $234.3 million, an improvement of 66% versus prior year Second Quarter 2026 Net Loss of $180.2 million worsening 1,402% versus prior year, largely due to a $191.3 million non-cash [...]
Standard BioTools Reports Second Quarter 2026 Financial Results
05/08/2026
BOSTON, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced financial results for the quarter ended June 30, 2026. Recent Highlights: [...]
OraSure Announces Second Quarter 2026 Financial Results
05/08/2026
BETHLEHEM, Pa., Aug. 05, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced its financial results for [...]
PacBio Announces Second Quarter 2026 Financial Results
05/08/2026
MENLO PARK, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended June 30, 2026. Recent Business Highlights Total revenue of $39.0 million was driven by [...]
Nyxoah Reports Second Quarter and First Half 2026 Financial and Operating Results
05/08/2026
REGULATED INFORMATION Nyxoah Reports Second Quarter and First Half 2026 Financial and Operating Results U.S. commercial execution driving continued launch momentum resulting in 22% sequential U.S. revenue growth in Q2 [...]
Nyxoah Publie ses Résultats Financiers et Opérationnels du Deuxième Trimestre et du Premier Semestre 2026
05/08/2026
INFORMATIONS RÉGLEMENTÉES Nyxoah Publie ses Résultats Financiers et Opérationnels du Deuxième Trimestre et du Premier Semestre 2026 L’exécution commerciale aux États-Unis soutient la dynamique du lancement et se traduit [...]
Biomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights
05/08/2026
Enrollment ongoing for the Phase II COVALENT-211 clinical trial in patients with insulin deficiency in Type 2 diabetes (“T2D”); data expected in the first quarter of 2027 Enrollment also ongoing for the Phase II [...]
Sight Sciences Reports Second Quarter 2026 Financial Results
05/08/2026
Raises Full-Year 2026 Revenue Guidance and Reduces Adjusted Operating Expense Guidance MENLO PARK, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an [...]
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05/08/2026
MALVERN, Pa., Aug. 05, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today [...]
RxSight, Inc. Reports Second Quarter 2026 Results and Provides Update on 2026 Outlook
05/08/2026
ALISO VIEJO, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today reported financial results for the quarter ended June 30, 2026, and provided an update on its 2026 financial outlook. Second [...]
Cytek Biosciences Reports Second Quarter 2026 Financial Results
05/08/2026
FREMONT, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the second [...]
Akebia Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights
05/08/2026
Q2 2026 Vafseo ® (vadadustat) net product revenues grew to $21.3 million ; more than 10,500 p atients now on therapy Advancement of rare kidney disease pipeline continues with initiation of Phase 2 open-label basket [...]
ADMA Biologics Reports Second Quarter 2026 Financial Results and Provides Business Update
05/08/2026
2Q 2026 Total Revenue of $124.4 Million, Increasing 2% Year-over-Year 2Q 2026 ASCENIV Revenue of $102.9 Million, Increasing 24% Year-over-Year BIVIGAM Utilization Stabilized with Sequential Improvement in Demand and [...]
Vaxcyte Reports Second Quarter 2026 Financial Results and Provides Business Update
05/08/2026
Topline Safety, Tolerability and Immunogenicity Data from VAX-31 Adult Phase 3 OPUS-1 Trial Expected in Fourth Quarter of 2026; OPUS-2 and OPUS-3 Phase 3 Results Expected in First Half of 2027 Topline Safety, [...]
Tenaya Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
05/08/2026
Positive Interim Data Shared in 2Q 2026 from the MyPEAK™-1 and RIDGE™-1 Clinical Trials Each Demonstrated Meaningful Improvements in Key Disease Characteristics Additional Data Releases Plus Updates on Regulatory [...]
Wave Life Sciences Announces Expected Completion Date for Redomiciliation to Delaware
05/08/2026
CAMBRIDGE, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- As previously announced, Wave Life Sciences Ltd. (NASDAQ: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to [...]

Pages